Lifesci Capital Has Pessimistic Outlook of CNTX Q1 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at Lifesci Capital reduced their Q1 2026 EPS estimates for Context Therapeutics in a research note issued to investors on Tuesday, March 24th. Lifesci Capital analyst C. Zhu now forecasts that the company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.13). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Context Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.62) EPS.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03).

Several other research analysts have also issued reports on the stock. JonesTrading began coverage on shares of Context Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target on the stock. Piper Sandler increased their price objective on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Guggenheim reissued a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Context Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $6.60.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $2.59 on Friday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.62. The stock has a market cap of $237.97 million, a P/E ratio of -6.82 and a beta of 1.96. The firm has a 50-day moving average of $2.48 and a two-hundred day moving average of $1.63.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in Context Therapeutics during the 4th quarter valued at about $3,824,000. Marshall Wace LLP lifted its position in shares of Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the period. Finally, Citadel Advisors LLC purchased a new position in Context Therapeutics during the third quarter valued at approximately $100,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

More Context Therapeutics News

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target, reflecting stronger upside expectations; this can boost investor sentiment and buying interest. Piper Sandler Raises Context Therapeutics Price Target
• Positive Sentiment: Guggenheim published a Buy rating on CNTX, another institutional endorsement that may support the rally. Guggenheim Buy Rating
• Positive Sentiment: D. Boral Capital issued a Buy rating, adding to the cluster of favorable analyst recommendations. D. Boral Capital Buy Rating
• Positive Sentiment: MSN reports a 13.33% increase in a published price target to $5.78, signaling bullish revision of fair value that can attract momentum traders. Price Target Increased to $5.78
• Negative Sentiment: Lifesci Capital cut multiple 2026 quarterly and full‑year EPS estimates (Q1–Q4 2026 and FY2026 now seen at about ($0.62) vs prior ~$($0.55)); the firm still carries a “Strong‑Buy” rating, but lowered earnings guidance increases short‑term downside risk if fundamentals or cash burn concerns persist.
• Negative Sentiment: HC Wainwright also trimmed Q1–Q4 2026 and multi‑year EPS forecasts (FY2026 lowered to ~$($0.60) from ~$($0.49) and later‑year estimates reduced), signaling analysts expect heavier near‑term losses than previously modeled — a negative for valuation and longer‑term profitability expectations.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.